Invasive intracranial tumors, particularly malignant gliomas, are very difficult to eradicate surgically and carry a dismal prognosis. The vast majority relapse locally indicating that their cure is dependent on radical and complete local excision. However, their ability to invade and hide among normal brain tissue, our inability to visualize and detect them, the low tolerance of brain tissue to ionizing radiation and the presence of the blood brain barrier are the main causes of our failure to eradicate them. Photodynamic detection with 100% specificity and more than 80% sensitivity offers an excellent chance of visualizing camouflaged tumor nests. Also, photodynamic therapy offers a very good chance of targeted destruction of the remaining tumor cells safely following surgical excision and may double the survival of patients harboring these awful tumors. More work needs to be done to refine this promising technology to exploit it to its full potential.
Introduction
The eradication of invasive intracranial tumors has eluded neurosurgeons and neuro-oncologists for many decades because; tumor cells are often impossible to distinguish from normal brain under normal surgical microscopy, many advancing edges of these malignant tumors remain invisible to current neuro-imaging, and infiltration of normal surrounding brain precludes safe radical tumor resection even in the era of image guided and computer assisted micro-neurosurgery. The cumulative nature of ionizing radiation limits the radiotherapy dose to the limit of brain-tolerance and the blood brain barrier (BBB) restricts the access and effectiveness of chemotherapeutic agents.
One of the most common invasive intracranial tumors is high-grade glioma (HGG) comprising more than 40% of all intracranial tumors and consists of Glioblastoma multiform (GBM 29%) and Anaplastic Astrocytoma (AA 11%). The current standard treatment of GBM and AA is surgery plus radiotherapy (4000 cGy whole brain + 1500 to 2000 cGy to tumor bed = 6000 cGy to the tumor) (1). This management protocol offers a mean survival of < 12 months to most patients and a two-year survival rate of < 7.5% (2). Furthermore, patients above the age of 65 years have a mean survival of about 30 weeks. Chemotherapy has no more than 30-40% partial response rate and in most circumstances 10-20% (3) response rate. The vast majority of these tumors recur locally indicating that a more aggressive local therapy is required to eradicate the "weeds" of tumor hiding among the "flowers" of the normal brain garden.
At the other end of the spectrum, the control rate of benign invasive intracranial tumors such as invasive pituitary adenomas is less than ideal. Surgery and adjuvant radiotherapy stands about 90% chance of local tumor control rate (4) of non-secreting adenomas and about 80% chance of cure of Growth-hormone secreting adenomas (5). These reasonable outcome figures are at the expense of panhypopituitrism, the risk of radionecrosis of the optic nerves, the optic chiasm or the hypothalamus and the development of a second cancer later on in life (6). Because of these poor results and the limitations of current therapies of invasive intracranial tumors, the search for the Holy Grail to eradicate these tumors more effectively continues. Could the Holy Grail be the use of light and photosensitizers?
The Scientific Basis of PDD/PDT in Brain
Both Photo-Dynamic Detection (PDD) and Photo-Dynamic Therapy (PDT) are based on the fact that photosensitizing agents are preferentially taken up and retained by brain tumor cells (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The concentration of the photosensitizers in some tumors reaches > 19 times that in normal brain cells (8, 14, 23) . Secondly, when the photosensitizing agents are exposed to light of particular wavelength, they absorb the light energy and become activated. The outcome of this process in PDD is fluorescence of tumor cells (10, 11, 15, 18, (24) (25) (26) (27) (28) (29) (30) (31) , which then can be sought and removed by the surgeon. In PDT, the outcome of the light activation of the photosensitizing agent is the accumulation of a highly active molecule; singlet oxygen 1 O2 (32, 33, 35) . This molecule is very cytotoxic leading to cell membrane damage (34, 35) and influx of calcium (36), collapse of tumor microcirculation (37) and loss of tumor cell adhesiveness (38) . The net effect of all these cellular damages is necrosis of glioma cells (7, 8, 10-15, 17, 19-21, 39-93) . The unwanted effect of this necrosis in a closed compartment such as the skull, is raised intracranial pressure (ICP) (48, 52, 57, 68) . Therefore, it is very important that cytoreductive therapy and measures to reduce ICP are undertaken after PDT of brain tumors. Furthermore, it has been demonstrated that PDT can exert its anti-cancer effects by programming tumor-cell death (Apoptosis) (46), which would be more welcome in brain as it would not be associated with as much cerebral oedema and raised intracranial pressure. If a way could be found to increase apoptosis, decrease cell necrosis and enhance the beneficial anti-tumor effects of PDT, then it would be possible to deliver PDT stereotactically and via minimally invasive techniques.
Photosensitizers
The number of photosensitizers investigated and used in the laboratory would be prohibitive to list in this article (7-93). However, the most commonly used photosensitizers today are 5-ALA, Photofrin and Foscan. These photosensitizers are not licensed at the moment for treating brain tumors and are used on a named patient's basis.
• 5-Aminolevulinic Acid (5ALA) (10, 11, 15, 18, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) 48) ◊ 5ALA has been used in many fields to detect and treat precancer and cancerous lesions. It can be applied topically or orally. In PDD and PDT of brain tumors it can be given 3-4 hours before induction of anaesthesia in a mixture of non-fizzy orange juice at 15-20 mg/Kg body weight. The active compound in the cells is protoporphyrin IX (PpIX), which accumulates in tumor cells and can be activated by violet-blue light (375-440 nm) for PDD and diode laser light (635 nm) for PDT. Tissue depth penetration is 7-15 mm, irradiation dose required for PDT is 100 J/cm 2 , and skin photosensitivity continues for 7-10 days after ingestion.
• Photofrin (Porfimer Sodium) (17, 52, 54) ◊ Photofrin is given intravenous at 2mg/Kg body weight 48 to 96 hours before PDT. It is activated by diode laser light at 630 nm wavelength. Depth of tissue penetration is from 7 to 12 mm and irradiation dose is 100 J/cm 2 . Skin photosensitivity carries on for 30 days after which it reduces and by 90 days it usually gone.
• Foscan (Temoporfin) ◊ Foscan is given intravenous at a dose of 0.15 mg/Kg body weight about 90-110 hours before PDT. It is activated at 652 nm wave length and its tissue penetration is 10-15 mm. The irradiation dose is 20 J/cm 2 and its skin photosensitivity continues for about 2 weeks.
Review of the Literature & Early Institutional Results
Experimental studies on glioma cell cultures (10, 11, 16, 21, 24, 40, 50, 53, 76) , glioma spheroids (30, 91) and glioma and gliosarcoma animal models (7, 9, 12-15, 17, 18, 27, 28, 31, 41, 48, 54, 57, 60, 63, 70, 79, 81-83, 87, 88) have established that both PDD and PDT have a consistent encouraging antitumor effect and that glioma cells preferentially take up and retain the Photosensitizer making them potential target for treatment. These experimental findings were confirmed in phase I/II clinical studies (8, 25, 26, 44, 45, 49) . Ferria, C. et al. (90) reported one of the earliest attempts to photoirradiate the post resection glioma cavity in humans and predicted that future refinement of the technique may produce better tissue penetration and more extensive tumor kill. Kaye, A. H. et al. (71) reported a phase I/II trial involving 23 patients, of which there were 13 new GBM, 6 recurrent GBM, 2 new AA and 1 recurrent AA. He used hematoporphyrin derivative administered 24 hours before treatment at 5-mg/Kg body weight. After radical tumor removal, the cavity was irradiated with 630 nm laser light. He used two different lasers to deliver the light and a dose variation from 70-230 J/cm 2 . Sixty-eight percent of the patients developed new tumors and underwent radiotherapy (20 Gy). Fiftyseven percent of the recurrent gliomas developed further recurrence in 12-16 weeks and 13% of the new gliomas developed recurrence at 3 and 13 weeks. Fifteen patients had no recurrence at a mean follow-up of 7 months (1-16 months). The authors concluded that PDT can be used as adjuvant therapy to surgery plus radiotherapy. By 1988, more than 64 treated patients with PDT were reported and although some of the initial results were disappointing, the majority of the treated patients had a low light dose and were of very poor prognosis (64). Kostron, H. et al. (44) reported his first 20 patients including 18 GBM treated with a wavelength of 630 nm and 40-120J/cm 2 . This was followed immediately with a single dose of radiation. Conventional radiotherapy followed in 8 patients. The median survival of 3 recurrent GBM was 5 months and 4 of newly diagnosed GBM died because of recurrence with a median survival of 5 months. However, 6 patients were still alive 12 months after PDT and 6 patients were still alive at 22 months. This was indeed very encouraging outcome, considering that the mean survival of these patients is < 12 months and the 2 year survival is <7.5%.
Origitano & Reichman (56) reported their experience using image guided computer assisted protocol to improve treatment volume coverage and pointed out that treatment failure is often due to lack of tumor coverage by the treatment and the limited tissue penetration of the laser light. They have demonstrated that combining intracavity irradiation with peritumoral interstitial irradiation was possible and could achieve wider tumor volume coverage. Muller and Wilson (49) reported 49 patients treated with PDT. These were young (mean age of 41) with a mean Karnofsky performance score of 79, who had recurrent malignant gliomas. Thirty-two were GBM, 14 were AA , 6 were mixed and 4 were malignant ependymomas. Treatment dose varied from 440 to 4500 J (median 1800J) and the energy density varied from 8-110J/cm 2 . The median survival of recurrent GBM was 30 weeks with a 1 year survival of 18%. The median survival of GBM from first diagnosis was 82% at 1 year and 57% at 2 years, which is significantly better than the 2 year survival of <7.5% following standard treatment. For recurrent AA the median survival was 44 weeks and the 1 year & 2 year survival was 43% and 36% respectively.
By 1996, more than 310 patients with newly diagnosed or recurrent malignant gliomas were treated with PDT after tumor resection (97). Although there was wide variation in the light irradiation dose, the photosensitizer dose, the completeness of surgical resection, the patient's age & functional performance score, the number of treatments received and the number of recurrences, analysis of the data indicated that PDT increased the survival of these patients significantly and the treatment was well tolerated. Our own institutional early results of an ongoing prospective trial confirm the aforementioned improved survival rates with minimal side effects.
The volume of tumor remaining after resection seems to be a significant adverse prognostic factor for recurrence of HGG. Therefore, complete tumor resection would seem to be the next logical step in the management of these unpleasant neoplasms. However, the most limiting factor to achieve complete resection safely is our inability to distinguish normal brain from tumor under normal surgical microscopy. Stummer et al. (25, 26, 96) had reported the utilization of PDD to achieve maximum tumor removal safely with 100% specificity and 85% sensitivity. In more than 60% of his consecutive 52 patients he managed to completely excise the enhancing GBM on MRI scan (96). Coupling this technology with the surgical microscope, had led to significant improvement in the survival rate (> 100 months -personal communication).
PDD and PDT was used with positive results not only in patients with very poor prognosis such as those harboring GBM or AA, but it was also used in malignant ependymomas (45, 49), malignant meningioma (44), melanoma brain metastasis (44), lung brain metastasis (71) and recurrent pituitary adenomas (97). We have used PDT in the treatment of recurrent hemangiopericytom, melanoma brain metastasis, recurrent pilocystic Astrocytoma and invasive pituitary adenomas with encouraging results.
Brain PDT Techniques and Limitations
The most favored method of brain tumor PDT is intracavity irradiation after radical surgical excision of high grade gliomas (44, 49, 71, 107) . The main limitation of this technique is the shallow tissue penetration of the laser light restricting the peritumoral photoradiation volume. However, this volume of tissue requiring treatment can be minimized by more complete tumor resection using PDD guided microsurgery (25, 26, 29, 96, 108) . The peritumoral treatment volume can be increased by combining intracavity irradiation with stereotactic peritumor interstitial photoradiation (56). Nevertheless, interstitial photoradiation on its own should be avoided in brain except in a very small lesion (<2 cm diameter) because of these aforementioned limitations of PDT and the increased risk of raised intracranial pressure due to tissue necrosis and cerebral oedema.
Brain oedema and necrosis have been observed in experimental models of gliomas and can lead to permanent neurological deficit. This was observed in some of the earlier series of brain tumor PDT (49). However, we did not encounter brain oedema in any of 23 treatments so far. Cerebral oedema is dependent on the photosensitizer dose, photoradiation dose and the time interval between photosensitizer administration and treatment (45, 48, 54, 87, 101) . Skin photosensitivity (102) may occur, but with proper patient/carer education about PDT and photosensitivity, this complication can be avoided. Kostron et al. (44) observed this in 20% of his early series and we have seen it in 2 (8.6%).
For adequate intracavity illumination it would be necessary to use a light diffuser most commonly a translucent balloon (44, 49, 80, 97) . The balloon is inflated to fill the post resection cavity and dose calculation is based on the balloon surface area in cm 2 . We inflated the balloon with a mixture of intralipid, saline and radio-opaque contrast material ( Figure  below) . We gave a dose of 100 J/cm 2 while in other studies a dose of 70 to 230 J/cm 2 was given (44, 71).
The intravenous injection is the preferred method of Photosensitizer administration because intratumoral or intratechal administration did not improve the uptake or the retention of Photosensitizer and led to more hemorrhagic complications (81, 92).
Conclusion
PDD/PDT in invasive intracranial tumors is safe treatment tolerated well by most patients. PDD maximizes surgical tumor resection leading to better prognosis and prolonged survival, while PDT gives significant improvement in survival of patients with malignant gliomas, who otherwise have dismal prognosis. However, the majority of patients treated so far had recurrent malignant disease with very poor prognosis. Although, it is quite clear that PDD/PDT on its own is not going to be curative in this awful disease, potential applications of PDD/PDT in this field are huge and have not been exploited to their full potential. Future studies should address the following questions:
• Does PDD guided surgical resection combined with PDT and immediate radiotherapy have better outcome than the standard therapy (55, 59, 79, 111)?
• Can the affinity of tumor cells to take up and retain the photosensitizers be exploited to its maximum potential by tagging chemotherapeutic agents (99, 104, 105, 109) , radioisotopes or gene therapy (100) to the photosensitizers?
• Can PDT be combined with Boron capture techniques (98, 106, 111)?
• Does PDT have a role in metastatic brain disease or more benign lesions (97)?
• Can we develop a better Photosensitizer, retaining the preferential up take and retention by tumor cells with no skin photosensitivity, and can we deliver it better to the target cells (103)?
